- $232.53bn
- $259.12bn
- $45.81bn
- 89
- 22
- 73
- 64
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Forxiga approved in Japan for CKD
AnnouncementREG - AstraZeneca PLC - ALXN1840 Wilson Phase III met primary endpoint
AnnouncementREG - BMO Cap & Inc InvTst - Portfolio Update
AnnouncementREG - AstraZeneca PLC - AZD7442 prophylaxis trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Update on Ultomiris Phase III ALS trial
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Update on US review of roxadustat
AnnouncementREG - AstraZeneca PLC - Enhertu head-to-head trial meets primary endpoint
AnnouncementREG - AstraZeneca PLC - Forxiga approved in the EU for CKD
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Saphnelo approved in the US for SLE
AnnouncementREG - AstraZeneca PLC - AZN: H1 2021 Results
AnnouncementREG - AstraZeneca PLC - Ultomiris recommended in EU for children with PNH
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Acquisition of Alexion completed
AnnouncementREG - BMO Cap & Inc InvTst - Portfolio Update
Announcement